An immunohistochemical double-staining three-marker kit for breast invasive carcinoma Ki-67 index interpretation
By using a mixed primary antibody of myoepithelial and glandular epithelial markers and Ki-67 antibody for immunohistochemical multiple staining on breast cancer tissue sections, the problem of distinguishing between invasive breast cancer and carcinoma in situ was solved, and the percentage of Ki-67 positive cells was accurately interpreted, reducing subjective errors.
Patent Information
- Application Number
- CN202210817868.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-07-12
- Publication Date
- 2025-10-24
- Estimated Expiration
- 2042-07-12
AI Technical Summary
In existing technologies, it is difficult to distinguish between invasive breast cancer and carcinoma in situ. The interpretation of the percentage of Ki-67 positive tumor cells is greatly influenced by the subjectivity of clinicians and pathologists, leading to biased results.
Using a mixed primary antibody consisting of myoepithelial marker antibody, glandular epithelial marker antibody, and Ki-67 antibody, the same breast or breast cancer tissue section was simultaneously labeled by immunohistochemical multiple staining. Combining morphological characteristics and color differences, the invasive carcinoma and carcinoma in situ, as well as the interstitial and lymphocyte regions, were accurately distinguished.
It enables accurate counting of Ki-67 positive cells in invasive cancer areas, reducing subjective errors and improving the accuracy and efficiency of interpretation.